Business · 28/05/2024Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Pfizer for PAXLOVID
Summary
The FDA has awarded a priority review voucher to Pfizer, the manufacturer of PAXLOVID, a material threat medical countermeasure product, following its approval on May 25, 2023.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →